Results 121 to 130 of about 4,828 (174)

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis. [PDF]

Cochrane Database Syst Rev
Garegnani L, Escobar Liquitay CM, Esteban I, Lenells M, Russo C, Bruschettini M, Franco JV, supported by Cochrane Sweden.   +7 more
europepmc   +1 more source

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce. [PDF]

Open Forum Infect Dis
Manzoni P, Baraldi E, Midulla F, Claris O, Dessardo S, Heikkinen T, Thwaites R, Paes B, Carbonell-Estrany X, Dobryanskyy D, Cetinkaya M, Al Harbi AS, Kang JM, Goh Eng Neo A, Chi H, Sant'Anna G, Villa Guillén M, Mariani GL, Safadi MAP, Urzua S, Zar HJ, Goussard P, Rodgers-Gray B, Waghorne N, Sanchez Luna M.   +24 more
europepmc   +1 more source

Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants. [PDF]

Hum Vaccin Immunother
Shin T, Lee JK, Kieffer A, Greenberg M, Wu J.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Palivizumab

Drugs, 1999
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
  +5 more sources

Comments on Palivizumab (Synagis)

Pediatrics, 1999
Caregivers and third-party payors need additional information from the Impact study1investigators to determine the appropriate use of palivizumab (Synagis) in select premature infants with increased risk of respiratory syncytial virus (RSV)-associated hospitalization.
F W, Moler, R W, Brown, R G, Faix, J R, Gilsdorf   +3 more
openaire   +2 more sources

Palivizumab: A debate about funding

Journal of Paediatrics and Child Health, 2010
AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic, Isaacs, David, Tobin, Bernadette   +2 more
openaire   +3 more sources

Improving the prescribing of palivizumab

Journal of Paediatrics and Child Health, 2018
AimPalivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.MethodsChildren prescribed palivizumab during the pre‐intervention period, 1 January 2013 until 31 ...
Simone Trist, Emily Horsley, Hala Katf, Natalie Tasker, Mona Mostaghim   +4 more
openaire   +2 more sources

Palivizumab: an overview

Hospital Medicine, 1999
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire   +2 more sources

Optimum Dosage Regimen of Palivizumab?

Therapeutic Drug Monitoring, 2002
Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections.
Zaaijer, Hans L., Vandenbroucke-Grauls, C. M. J. E., Franssen, E. J. F.   +2 more
openaire   +3 more sources

Palivizumab prophylaxis in ‘late preterm’ newborns

The Journal of Maternal-Fetal & Neonatal Medicine, 2010
In the last decades the preterm birth rate rose more than 20%, largely because of an increase among deliveries of 'late preterm' infants, i.e. those born at 34 to 36 weeks gestational age. Late preterm infants are more susceptible to infection by pathogens, such as respiratory syncytial virus (RSV), possibly because of the immaturity of both the ...
LANARI, MARCELLO, Silvestri, Michela, Rossi, Giovanni A.   +2 more
openaire   +3 more sources